Journals / Hacettepe Journal of Biology and Chemistry / 2020 / Cilt: 48 - Sayı: 3

Disulfide-Rich Peptides in Drug Development

İlaç Geliştirmede Disülfit-Zengin Peptidler

Pages
219–229
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review describes the structure and bioactivity of disulfide-rich peptides and their development with variousmodifications to become candidate molecules in drug design and development studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Peptides are important biomolecules in drug development with their high specificities to their targets.
📊
Key Findings & Data:Many peptidebaseddrug candidates have been increasingly involved in clinical and preclinical studies.
💡
Conclusion & Impact:This review describes the structure and bioactivity of disulfide-rich peptides and their development with variousmodifications to become candidate molecules in drug design and development studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Peptides are important biomolecules in drug development with their high specificities to their targets. Many peptidebaseddrug candidates have been increasingly involved in clinical and preclinical studies. Unfortunately, peptides havesome disadvantages such as poor metabolic stability, poor oral bioavailability and high production costs. These problemscan be overcome by modifications that have been inspired from highly stable disulfide-rich peptides already found innature. This review describes the structure and bioactivity of disulfide-rich peptides and their development with variousmodifications to become candidate molecules in drug design and development studies.

Özet

Peptidler, ilaç geliştirmede hedeflerine yüksek özgüllükleri olan önemli biyomoleküllerdir. Birçok peptid-bazlı ilaç adayı, klinik ve preklinik çalışmalarda giderek daha fazla yer almaktadır. Ne yazık ki, peptidlerin zayıf metabolik stabilite, zayıf oral biyoyararlanım ve yüksek üretim maliyetleri gibi bazı dezavantajları vardır. Bu problemler, hali hazırda doğada bulunan oldukça stabil disülfit bakımından zengin peptidlerden ilham alınarak yapılan modifikasyonlar ile çözülebilir. Bu derlemede disülfit-zengin peptidlerin yapı ve biyoaktiviteleri ve ilaç tasarım ve geliştirme çalışmalarında aday moleküller haline gelmek için çeşitli modifikasyonlarla geliştirilmeleri anlatılmaktadır.

🔖

Cite This Article

AKCAN, M., KARA, Ş. (2022). Disulfide-Rich Peptides in Drug Development. Hacettepe Journal of Biology and Chemistry, Cilt: 48 - Sayı: 3, 219–229. https://ajindex.com/articles/528988

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. P. Chames, M. Van Regenmortel, E. Weiss, D. Baty, Therapeutic antibodies: successes, limitations and hopes for the future, Br. J. Pharmacol., 157 (2009) 220-233
  2. N. Munoz-Durango, M.S. Pizarro-Ortega, E. Rey-Jurado, F.E. Diaz, S.M. Bueno, A.M. Kalergis, Patterns of antibody response during natural hRSV infection: insights for the development of new antibody-based therapies, Expert Opin. Investig. Drugs, 27 (2018) 721-731
  3. T.M. Pierpont, C.B. Limper, K.L. Richards, Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy, Front. Oncol., 8 (2018) 163
  4. J.L. Lau, M.K. Dunn, Therapeutic peptides: Historical perspectives, current development trends, and future directions, Bioorg. Med. Chem., (2017) 2700-2707
  5. R. Koradi, M. Billeter, K. Wuthrich, MOLMOL: A program for display and analysis of macromolecular structures, J. Mol. Graph., 14(1996) 51-55
  6. Ş. Kara, Tümör ile ilişkili peptidlerin sentezi ve kararlılıklarının incelenmesi-Synthesis and examination of stabilities of tumor-related peptides, M.Sc. Thesis, Number: 529178, Kütahya Dumlupınar University, Graduate School of Sciences, 2018
  7. L. Thorstholm, D.J. Craik, Discovery and applications of naturally occurring cyclic peptides, Drug Discov. Today Technol., 9 (2012) e1-e70
  8. J. Koehbach, D.J. Craik, The Vast Structural Diversity of Antimicrobial Peptides, Trend. Pharmaco. Sci., 40 (2019) 517-528
  9. J.F. Borel, C. Feurer, H.U. Gubler, H. Stahelin, Biological effects of cyclosporin A: a new antilymphocytic agent, Agents Actions, 6 (1976) 468-475
  10. C. Spitzfaden, H.P. Weber, W. Braun, J. Kallen, G. Wider, H. Widmer, M.D. Walkinshaw, K. Wuthrich, Cyclosporin A-cyclophilin complex formation. A model based on X-ray and NMR data, FEBS Lett., 300 (1992) 291-300
  11. X. Yang, P. Feng, Y. Yin, K. Bushley, J.W. Spatafora, C. Wang, Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment, mBio, 9 (2018) e01211-01218
  12. J. Klages, C. Neubauer, M. Coles, H. Kessler, B. Luy, Structure refinement of cyclosporin a in chloroform by using RDCs measured in a stretched PDMS-gel, Chembiochem., 6 (2005) 1672-1678
  13. J.C. O’Shea, J.E. Tcheng, Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa, Expert Opin. Pharmacother., 3 (2002) 1199-1210
  14. D.W. Cushman, M.A. Ondetti, History of the design of captopril and related inhibitors of angiotensin converting enzyme, Hypertension, 17 (1991) 589